Shenzhen Fifth People's Hospital Report issue

Academic/Hospital Phase 1 Phase 4

Organization Overview

First Clinical Trial
2018
NCT03662477
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Shenzhen Fifth People's Hospital

Active Ingredients

Drugs in Phase 4 Trials (2)

megestrol (megace) (1 trial)

thalidomide (Thalomid) (1 trial)

Drugs in Phase 1 Trials (1)

autologous natural killer cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Adenocarcinoma of Lung (Phase 1)

Neoplasms, Second Primary (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3